Form 4: Pulmonx CCO Sells Shares for Tax, Receives New RSU Grant

Pulmonx's Chief Commercial Officer, Geoffrey Beran Rose, sold shares to cover tax obligations related to RSU vesting and received a new grant of 100,000 Restricted Stock Units.

Summary

• Geoffrey Beran Rose, Chief Commercial Officer of Pulmonx Corp (LUNG), reported transactions on March 2, 2026.
• Sold a total of 7,732 shares of common stock at $1.43 per share to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs) granted between March 1, 2022, and March 3, 2025.
• Received a new grant of 100,000 Restricted Stock Units (RSUs) payable solely in common stock, with a grant price of $0.
• These new RSUs will vest in equal quarterly installments over a four-year period starting from the grant date of March 2, 2026.
• Following these transactions, the reporting person's direct beneficial ownership of common stock increased to 465,734 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive event. While there were sales, they were for tax purposes, which is routine. The significant new RSU grant demonstrates continued commitment and long-term incentive for a key executive.

Positives

• The grant of 100,000 Restricted Stock Units (RSUs) indicates continued long-term incentive and alignment of the Chief Commercial Officer's interests with shareholders.
• The RSU grant, vesting over four years, suggests management stability and a commitment to future performance.

Negatives

• The sale of 7,732 shares, totaling $11,055.56 (7732 * $1.43), reduces the officer's direct ownership, although it was for tax withholding purposes.

Future Outlook

The new RSU grant vesting over four years from March 2, 2026, indicates a long-term incentive structure for the Chief Commercial Officer, aligning future compensation with company performance over this period.

Industry Context

StockSavvy.ai notes that the grant of Restricted Stock Units (RSUs) is a common form of executive compensation in the medical device and biotechnology sectors, designed to align executive incentives with long-term shareholder value creation. The sale of shares to cover tax obligations upon RSU vesting is also a standard practice across industries, not indicative of a change in sentiment towards the company.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a significant component of executive compensation is consistent with practices observed in comparable medical technology companies such as Intuitive Surgical (ISRG) or Medtronic (MDT), where long-term equity incentives are prevalent.
• The four-year vesting schedule for the RSU grant aligns with typical industry standards for executive retention and performance incentives, similar to programs at companies like Stryker (SYK) or Zimmer Biomet (ZBH).

Stakeholder Impact

• Shareholders: The new RSU grant aligns the Chief Commercial Officer's long-term interests with shareholder value creation, potentially fostering sustained performance. The tax-related sales are minor in the context of the new grant and overall ownership.
• Employees: The compensation structure for a key executive may serve as a benchmark or signal for broader employee incentive programs.

Next Steps

• The newly granted 100,000 RSUs will vest in equal quarterly installments over the four-year period from March 2, 2026.

Key Dates

Recommendation

The filing details routine insider transactions involving tax-related sales and a new RSU grant for a key executive. These actions are standard compensation practices and do not provide new fundamental information to warrant a change in investment thesis. The new RSU grant aligns executive incentives with long-term company performance, which is a positive, but the overall impact on the company's valuation or operational outlook is neutral. Therefore, a "hold" recommendation is appropriate, maintaining current positions while awaiting more substantive operational or financial updates.

Keywords

Pulmonx, LUNG, Geoffrey Beran Rose, Chief Commercial Officer, CCO, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Grant, Stock Sales, Tax Withholding, Beneficial Ownership